|
Mar 25
|
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
|
|
Jan 23
|
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
|
|
Dec 5
|
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
|
|
Nov 30
|
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
|
|
Nov 13
|
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 9
|
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
|
|
Nov 2
|
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
|
|
Sep 7
|
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
|
|
Sep 6
|
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
|
|
Sep 5
|
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
|
|
Apr 25
|
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
|